Limmahakhun S, Chaiwarith R, Nuntachit N, Sirisanthana T, Supparatpinyo K
Department of Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai 50200, Thailand.
Int J STD AIDS. 2012 Jun;23(6):414-8. doi: 10.1258/ijsa.2012.011291.
Thailand has been greatly affected by the tuberculosis (TB) and HIV syndemic. This study aimed to determine treatment outcomes among HIV/TB co-infected patients. A retrospective cohort study was conducted at Chiang Mai University Hospital from 1 January 2000 to 31 December 2009. Of 171 patients, 100 patients were male (58.5%) and the mean age was 36.8 ± 8.0 years. Seventy-two patients (42.1%) had pulmonary tuberculosis. Median CD4+ count before TB treatment was 69 cells/mm(3) (interquartile range [IQR] 33, 151). The overall mortality was 3.5% (6 patients). Immune reconstitution inflammatory syndrome (IRIS) occurred in eight patients (6.0%). Disseminated TB infections increased risk of death (odds ratio [OR] = 2.55, 95% confidence interval [CI] 1.25, 5.18) and IRIS (OR = 9.16, 95% CI 1.67, 50.07). Initiating combination antiretroviral therapy (cART) within two months after TB treatment increased risk of IRIS (OR = 6.57, 95% CI 1.61-26.86) and physicians caring for HIV/TB co-infected patients should be aware of this condition.
泰国深受结核病和艾滋病并发流行的影响。本研究旨在确定艾滋病毒/结核病合并感染患者的治疗结果。2000年1月1日至2009年12月31日在清迈大学医院进行了一项回顾性队列研究。171例患者中,100例为男性(58.5%),平均年龄为36.8±8.0岁。72例患者(42.1%)患有肺结核。结核病治疗前CD4+细胞计数中位数为69个细胞/mm³(四分位间距[IQR]33,151)。总死亡率为3.5%(6例患者)。8例患者(6.0%)发生了免疫重建炎症综合征(IRIS)。播散性结核感染增加了死亡风险(比值比[OR]=2.55,95%置信区间[CI]1.25,5.18)和IRIS风险(OR=9.16,95%CI 1.67,50.07)。在结核病治疗后两个月内开始联合抗逆转录病毒治疗(cART)增加了IRIS风险(OR=6.57,95%CI 1.61 - 26.86),治疗艾滋病毒/结核病合并感染患者的医生应了解这种情况。